
Seong Gu Heo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2200269/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion–Driven NSCLC. Cancer Discovery, 2020, 10, 1194-1209.	9.4	158
2	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-NaÃ⁻ve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3287-3295.	7.0	66
3	Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 4397-4409.	7.0	49
4	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. Scientific Reports, 2019, 9, 19909.	3.3	18
5	Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer. European Journal of Cancer, 2021, 153, 179-189.	2.8	16
6	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210791.	3.2	10
7	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Cancer Medicine, 2021, 10, 7012-7020.	2.8	8
8	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. Frontiers in Oncology, 2022, 12, 821391.	2.8	6
9	The Liability Threshold Model for Predicting the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Multi-Cohort Study of Korean Adults. Metabolites, 2021, 11, 6.	2.9	3
10	Abstract LB515A: A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations. Cancer Research, 2022, 82, LB515A-LB515A.	0.9	1
11	Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs. Cancer Research, 2022, 82, LB544-LB544.	0.9	0